Kinexus Bioinformatics Corporation has released its first Kinex™ antibody microarray kit with its latest generation KAM-850 chip. The new antibody microarray is capable of tracking the levels and functional states of hundreds of diverse proteins in human and animal cell and tissue specimens and features more than 330 phosphosite- and 540 pan-specific antibody probes making it a reliable proteomics tool to study changes in cell signaling proteins that occur in response to a range of treatments, drugs, toxins, pathological and other experimental conditions.
“By offering the most affordable and highest quality antibody microarrays, we enable scientists to conduct proteome-wide screening in their own laboratories to further advance signal transduction research that will ultimately help improve patient care,” said Dr. Steven Pelech, president and founder of Kinexus and a professor in the Division of Neurology at the University of British Columbia. “We have already used our Kinex™ antibody microarray to successfully identify panels of candidate biomarkers for Alzheimer’s disease and ALS that we are hoping to develop as diagnostic targets.”
Kinexus currently has agreements with over 1,700 research laboratories in companies, universities, government institutions and hospitals in over 35 different countries.
